Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.…
Aytu BioPharma (AYTU) Stock Sees Fair Value Lift After Rosemont Deal Recast Analyst Views
Aytu BioPharma (NASDAQ: AYTU) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 75 employees.
The shares were at 2.660 USD on 20 November 2026, up 31.0% over 52 weeks. Its 52-week range is 1.750 USD to 3.070 USD: the price is 13.4% below the high and 52.0% above the low.
Its market capitalisation is 28.91M USD.
Aytu BioPharma reports return on equity of -40.4%, an operating margin of -18.4% and revenue up 6.9% year over year.
It holds more cash than debt, a net cash position of 8.98M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 8.850 USD is 232.7% above the current price.